This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
濾胞性リンパ腫ガイドライン
渡 辺 隆
Key words : Watchful wait, Rituximab, Radiotherapy, Radioimmunotherapy
き治療ということになる。Watch and waitできる患者を選択するには熟練を要するといえよう。
著者の COI(conflicts of interest)開示:渡辺隆;講演料(中外
製薬株式会社,全薬工業株式会社,エーザイ株式会社)
文 献
1)Lymphoma Study Group of Japanese Pathologists. TheWorld Health Organization Classification of MalignantLymphomas in Japan: Incidence of recently recognizedentities. Pathol Int. 2000; 50: 696-702.
2)Izumo T, Maseki N, Mori S, Tsuchiya E. Practical Utility ofthe revised European-American classification of lymphoidneoplasms for Japanese non-Hodgkin=s lymphomas. Jpn JCancer Res. 2000; 91: 351-360.
3)Rosenberg SA. Karnofsky memorial lecture. The low-gradenon-Hodgkin=s lymphomas: challenges and opportunities. JClin Oncol. 1985; 3: 299-310.
4)The International Non-Hodgkin=s Lymphoma Prognostic Fac-tors Project. A predictive model for aggressive non-Hodgkin=s lymphoma. N Engl J Med. 1993; 329: 987-994.
5)López-Guillermo A, Montserrat E, Bosch F, Terol MJ, CampoE, Rozman C. Applicability of the International Index foraggressive lymphomas to patients with low-grade lympho-ma. J Clin Oncol. 1994; 12: 1343-1348.
6)Hermans J, Krol AD, van Groningen K, et al. InternationalPrognostic Index for aggressive non-Hodgkin=s lymphoma isvalid for all malignancy grades. Blood. 1995; 86: 1460-1463.
7)Solal-Céligny P, Roy P, Colombat P, et al. Follicular lympho-ma international prognostic index. Blood. 2004; 104: 1258-1265.
8)Federico M, Bellei M, Marcheselli L, et al. Follicular lympho-ma international prognostic index 2: a new prognostic indexfor follicular lymphoma developed by the internationalfollicular lymphoma prognostic factor project. J Clin Oncol.2009; 27: 4555-4562.
9)MacManus MP, Hoppe RT. Is radiotherapy curative for stageI and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford Universi-ty. J Clin Oncol. 1996; 14: 1282-1290.
10)Horning SJ, Rosenberg SA. The natural history of initiallyuntreated low-grade non-Hodgkin=s lymphomas. N Engl JMed. 1984; 311: 1471-1475.
11)Apostolidis J, Gupta RK, Grenzelias D, et al. High-dosetherapy with autologous bone marrow support as consolida-tion of remission in follicular lymphoma: long-term clinicaland molecular follow-up. J Clin Oncol. 2000; 18: 527-536.
12)Buchegger F, Press OW, Delaloye AB, Ketterer N. Radiola-beled and native antibodies and the prospect of cure offollicular lymphoma. Oncologist. 2008; 13: 657-667.
13)Ardeshna KM, Smith P, Norton A, et al. Long-term effect of awatch and wait policy versus immediate systemic treatmentfor asymptomatic advanced-stage non-Hodgkin lymphoma: arandomised controlled trial. Lancet. 2003; 362: 516-522.
14)Gribben JG. How I treat indolent lymphoma. Blood. 2007;109: 4617-4626.
15)Brice P, Bastion Y, Lepage E, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatmentpolicy, prednimustine, or interferona: a randomized studyfrom the Groupe d=Etude des Lymphomes Folliculaires.Groupe d=Etude des Lymphomes de l=Adulte. J Clin Oncol.1997; 15: 1110-1117.
16)Solal-Céligny P, Lepage E, Brousse N, et al. Doxorubicin-containing regimen with or without interferona-2b for ad-vanced follicular lymphomas: final analysis of survival andtoxicity in the Groupe d=Etude des Lymphomes Folliculaires86 Trial. J Clin Oncol. 1998; 16: 2332-2338.
17)Hiddemann W, Kneba M, Dreyling M, et al. Frontlinetherapy with rituximab added to the combination of cyclo-phosphamide, doxorubicin, vincristine, and prednisone(CHOP) significantly improves the outcome for patients withadvanced-stage follicular lymphoma compared with therapywith CHOP alone: results of a prospective randomized studyof the German Low-Grade Lymphoma Study Group. Blood.2005; 106: 3725-3732.
18)Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, andprednisone alone in patients with previously untreated ad-vanced follicular lymphoma. J Clin Oncol. 2008; 26: 4579-4586.
19)Schulz H, Bohlius JF, Trelle S, et al. Immunochemotherapywith rituximab and overall survival in patients with indolentor mantle cell lymphoma: a systematic review and meta-anal-ysis. J Natl Cancer Inst. 2007; 99: 706-714.
20)Fisher RI, LeBlanc M, Press OW, Maloney DG, Unger JM,Miller TP. New treatment options have changed the survivalof patients with follicular lymphoma. J Clin Oncol. 2005; 23:8447-8452.
21)Peterson BA, Petroni GR, Frizzera G, et al. Prolonged single-agent versus combination chemotherapy in indolent follicularlymphomas: a study of the cancer and leukemia group B. JClin Oncol. 2003; 21: 5-15.
22)Brice P, Bastion Y, Lepage E, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatmentpolicy, prednimustine, or interferona: a randomized studyfrom the Groupe d=Etude des Lymphomes Folliculaires.Groupe d=Etude des Lymphomes de l=Adulte. J Clin Oncol.1997; 15: 1110-1117.
23)Colombat P, Salles G, Brousse N, et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for pa-tients with follicular lymphoma with a low tumor burden:clinical and molecular evaluation. Blood. 2001; 97: 101-106.
24)Witzig TE, Vukov AM, Habermann TM, et al. Rituximabtherapy for patients with newly diagnosed, advanced-stage,follicular grade I non-Hodgkin=s lymphoma: a phase II trial inthe North Central Cancer Treatment Group. J Clin Oncol.2005; 23: 1103-1108.
25)Colombat P, Brousse N, Salles G, et al. Rituximab inductionimmunotherapy for first-line low-tumor-burden follicular lym-phoma: survival analyses with 7-year follow-up. Ann Oncol.2012; 23: 2380-2385.
26)Pendlebury S, el Awadi M, Ashley S, Brada M, Horwich A.Radiotherapy results in early stage low grade nodal non-Hodgkin=s lymphoma. Radiother Oncol. 1995; 36: 167-171.
27)Pugh TJ, Ballonoff A, Newman F, Rabinovitch R. Improvedsurvival in patients with early stage low-grade follicular lym-phoma treated with radiation: a Surveillance, Epidemiology,and End Results database analysis. Cancer. 2010; 116: 3843-3851.
28)Seymour JF, Pro B, Fuller LM, et al. Long-term follow-up of aprospective study of combined modality therapy for stage I-IIindolent non-Hodgkin=s lymphoma. J Clin Oncol. 2003; 21:2115-2122.
29)Kelsey SM, Newland AC, Hudson GV, Jelliffe AM. A BritishNational Lymphoma Investigation randomised trial of singleagent chlorambucil plus radiotherapy versus radiotherapyalone in low grade, localised non-Hodgkins lymphoma. MedOncol. 1994; 11: 19-25.
30)Friedberg JW, Byrtek M, Link BK, et al. Effectiveness of first-line management strategies for stage I follicular lymphoma:analysis of the National LymphoCare Study. J Clin Oncol.2012; 30: 3368-3375.
31)Advani R, Rosenberg SA, Horning SJ. Stage I and II follicularnon-Hodgkin=s lymphoma: long-term follow-up of no initialtherapy. J Clin Oncol. 2004; 22: 1454-1459.
32)Salles G, Seymour JF, Offner F, et al. Rituximab maintenancefor 2 years in patients with high tumour burden follicular lym-phoma responding to rituximab plus chemotherapy (PRI-MA): a phase 3, randomised controlled trial. Lancet. 2011;377: 42-51.
33)McLaughlin P, Grillo-López AJ, Link BK, et al. Rituximabchimeric anti-CD20 monoclonal antibody therapy for re-lapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998; 16: 2825-2833.
臨 床 血 液 54:10
207(1753)
34)Friedberg JW, Cohen P, Chen L, et al. Bendamustine in pa-tients with rituximab-refractory indolent and transformednon-Hodgkin=s lymphoma: results from a phase II multicen-ter, single-agent study. J Clin Oncol. 2008; 26: 204-210.
35)Kahl BS, Bartlett NL, Leonard JP, et al. Bendamustine iseffective therapy in patients with rituximab-refractory,indolent B-cell non-Hodgkin lymphoma: results from aMulticenter Study. Cancer. 2010; 116: 106-114.
36)Robinson KS, Williams ME, van der Jagt RH, et al. Phase IImulticenter study of bendamustine plus rituximab in patientswith relapsed indolent B-cell and mantle cell non-Hodgkin=slymphoma. J Clin Oncol. 2008; 26: 4473-4479.
37)Forstpointner R, Dreyling M, Repp R, et al. The addition ofrituximab to a combination of fludarabine, cyclophospha-mide, mitoxantrone (FCM) significantly increases theresponse rate and prolongs survival as compared with FCMalone in patients with relapsed and refractory follicular andmantle cell lymphomas: results of a prospective randomizedstudy of the German Low-Grade Lymphoma Study Group.Blood. 2004; 104: 3064-3071.
38)van Oers MH, Klasa R, Marcus RE, et al. Rituximab mainte-nance improves clinical outcome of relapsed/resistantfollicular non-Hodgkin lymphoma in patients both with andwithout rituximab during induction: results of a prospectiverandomized phase 3 intergroup trial. Blood. 2006; 108: 3295-3301.
39)Kaminski MS, Estes J, Zasadny KR, et al. Radioimmunothera-py with iodine 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-termfollow-up of the University of Michigan experience. Blood.2000; 96: 1259-1266.
40)Emmanouilides C, Witzig TE, Gordon LI, et al. Treatmentwith yttrium 90 ibritumomab tiuxetan at early relapse is safeand effective in patients with previously treated B-cell non-Hodgkin=s lymphoma. Leuk Lymphoma. 2006; 47: 629-636.
41)Morschhauser F, Radford J, Van Hoof A, et al. Phase III trialof consolidation therapy with yttrium-90-ibritumomab tiuxe-tan compared with no additional therapy after first remissionin advanced follicular lymphoma. J Clin Oncol. 2008; 26:5156-5164.
42)Sebban C, Mounier N, Brousse N, et al. Standard chemother-apy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation inuntreated patients with advanced follicular lymphoma: theGELF-94 randomized study from the Groupe d=Etude desLymphomes de l=Adulte (GELA). Blood. 2006; 108: 2540-2544.
43)Deconinck E, Foussard C, Milpied N, et al. High-dosetherapy followed by autologous purged stem-cell transplanta-tion and doxorubicin-based chemotherapy in patients withadvanced follicular lymphoma: a randomized multicenterstudy by GOELAMS. Blood. 2005; 105: 3817-3823.
44)Lenz G, Dreyling M, Schiegnitz E, et al. Myeloablativeradiochemotherapy followed by autologous stem cell trans-plantation in first remission prolongs progression-freesurvival in follicular lymphoma: results of a prospective,randomized trial of the German Low-Grade Lymphoma StudyGroup. Blood. 2004; 104: 2667-2674.
45)Ladetto M, De Marco F, Benedetti F, et al. Prospective,multicenter randomized GITMO/IIL trial comparing inten-sive (R-HDS) versus conventional (CHOP-R) chemoim-munotherapy in high-risk follicular lymphoma at diagnosis:the superior disease control of R-HDS does not translate intoan overall survival advantage. Blood. 2008; 111: 4004-4013.
46)Gyan E, Foussard C, Bertrand P, et al. High-dose therapyfollowed by autologous purged stem cell transplantation anddoxorubicin-based chemotherapy in patients with advancedfollicular lymphoma: a randomized multicenter study by theGOELAMS with final results after a median follow-up of 9years. Blood. 2009; 113: 995-1001.
47)Sebban C, Brice P, Delarue R, et al. Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse inpatients with follicular lymphoma: a GELA study. J ClinOncol. 2008; 26: 3614-3620.
48)Le Gouill S, De Guibert S, Planche L, et al. Impact of the useof autologous stem cell transplantation at first relapse both innaïve and previously rituximab exposed follicular lymphomapatients treated in the GELA/GOELAMS FL2000 study.Haematologica. 2011; 96: 1128-1135.
49)van Besien K, Loberiza FR Jr, Bajorunaite R, et al.Comparison of autologous and allogeneic hematopoieticstem cell transplantation for follicular lymphoma. Blood.2003; 102: 3521-3529.
50)Bierman PJ, Sweetenham JW, Loberiza FR Jr, et al.Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin=s lymphoma: a comparison with allogeneic andautologous transplantation The Lymphoma Working Com-mittee of the International Bone Marrow Transplant Registryand the European Group for Blood and Marrow Transplanta-tion. J Clin Oncol. 2003; 21: 3744-3753.
51)Hosing C, Saliba RM, McLaughlin P, et al. Long-term resultsfavor allogeneic over autologous hematopoietic stem celltransplantation in patients with refractory or recurrentindolent non-Hodgkin=s lymphoma. Ann Oncol. 2003; 14:737-744.
52)Ingram W, Devereux S, Das-Gupta EP, et al. Outcome ofBEAM-autologous and BEAM-alemtuzumab allogeneic trans-plantation in relapsed advanced stage follicular lymphoma.Br J Haematol. 2008; 141: 235-243.
53)Rohatiner AZ, Nadler L, Davies AJ, et al. Myeloablativetherapy with autologous bone marrow transplantation forfollicular lymphoma at the time of second or subsequentremission: long-term follow-up. J Clin Oncol. 2007; 25: 2554-2559.
−臨 床 血 液−
208(1754)
54)Khouri IF, Saliba RM, Giralt SA, et al. Nonablative allogenichematopoietic transplantation as adoptive immunotherapyfor indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood.2001; 98: 3595-3599.
55)Tomblyn MR, Ewell M, Bredeson C, et al. Autologous versusreduced-intensity allogeneic hematopoietic cell transplanta-tion for patients with chemosensitive follicular non-Hodgkinlymphoma beyond first complete response or first partialresponse. Biol Blood Marrow Transplant. 2011; 17: 1051-
1057.56)Hari P, Carreras J, Zhang MJ, et al. Allogeneic transplants in
follicular lymphoma: higher risk of disease progression afterreduced-intensity compared to myeloablative conditioning.Biol Blood Marrow Transplant. 2008; 14: 236-245.
57)Avivi I, Montoto S, Canals C, et al. Matched unrelated donorstem cell transplant in 131 patients with follicular lymphoma:an analysis from the Lymphoma Working Party of theEuropean Group for Blood and Marrow Transplantation. Br JHaematol. 2009; 147: 719-728.